Bivalent Booster Necessary and Encouraged for Patients

The Division of Public Health (DPH) Interim Director, Rick Hong, MD, has asked MSD to share an important message on bivalent boosters with the membership. Read the full communication.

DPH is significantly concerned about the low uptake of bivalent boosters in our state. Currently, only 14.9% of the eligible population has received one; and more concerning, less than half of the vulnerable 65+ population (40%).  In his message, Dr. Hong shares the newest findings of the Centers for Disease Control and Prevention (CDC) in their latest MMWR and included in the DPH Health Alert Network notification (refer to the following article) regarding the importance of the COVID-19 bivalent booster in protecting against the disease.

As medical professionals, you know that what you tell your patients matters – how you explain the need for various vaccines, treatments, and tests is even more important. Please take the time to initiate the conversation about bivalent boosters with your patients and clearly explain the necessity of these potentially life-saving inoculations. For assistance, DPH has provided materials easily available for download at covidmaterialsde.com for you to post in your office and share with your patients.

Bivalent mRNA Effectiveness in Preventing Symptomatic Infection

The Delaware Division of Public Health (DPH) issued a health advisory to Delaware physicians on the effectiveness of bivalent mRNA vaccines in preventing symptomatic SARS-CoV-2 infection.

Monovalent mRNA COVID-19 vaccines were less effective against symptomatic infection during the period of SARS-CoV-2 Omicron variant predominance. In this study of vaccine effectiveness of the U.S.-authorized bivalent mRNA booster formulations, bivalent boosters provided significant additional protection against symptomatic SARS-CoV-2 infection in persons who had previously received two, three, or four monovalent vaccine doses. Due to waning immunity of monovalent doses, the benefit of the bivalent booster increased with time since receipt of the most recent monovalent vaccine dose. All persons should stay up to date with recommended COVID-19 vaccinations, including bivalent booster doses for eligible persons.

Note: Tables and references can be viewed via the health advisory link above or online at the original version of the MMWR at https://www.cdc.gov/mmwr/volumes/71/wr/mm7148e1.htm?s_cid=mm7148e1_w.

Removal of Emergency Use Authorization of Bebtelovimab

The Delaware Division of Public Health (DPH), Office of Emergency Services and Hospital Preparedness issued updated guidance on the administration of bebtelovimab. On November 30, 2022, The U.S. Food and Drug Administration (FDA) announced that bebtelobimab is not currently authorized for emergency use in the U.S. because it is not expected to neutralize Omicron subvariants BQ.1 and BQ.1.1. Data from the Centers for Disease Control and Prevention (CDC) estimates that the combined proportion of COVID-19 cases caused by the Omicron BQ.1 and BQ.1.1 subvariants to be above 57% nationally with a sustained trend of increasing prevalence across all regions. Given that a COVID-19 infection is likely to be caused by a non-susceptible SARS-CoV-2 variant, and consistent with the terms and conditions of the Letter of Authorization, bebtelovimab is not currently authorized for emergency use in any U.S region at this time. The U.S. Government recommends all product be retained in the event that SARS-CoV-2 variants susceptible to bebtelovimab, which are currently circulating at lower prevalence, become more prevalent in the future in the United States. Retained product must be appropriately held in accordance with storage conditions detailed in the authorized Fact Sheet for Health Care Providers and the Letter of Authorization for bebtelovimab. Physicians should use other approved or authorized products that are expected to retain activity against BQ.1 and BQ.1.1 as they choose appropriate treatment options for patients (Paxlovid, Veklury, Lagevrio, and convalescent plasma). Access the State Health Operations Center (SHOC) Resource Form for COVID Therapeutics.

Improving Ease of Access and Potential for Equitable Availability

On November 14, the U.S. Department of Health and Human Services (HHS) opened ordering to jurisdictional and federal entity administration partners for a limited amount of the updated (bivalent) Pfizer-BioNTech COVID-19 vaccine for people 12 years of age or older in single-dose vials. This vial presentation is in response to widespread requests from vaccine administration partners for the greater flexibility this presentation provides. This limited introduction of single-dose vials is designed to allow partners to offer the updated COVID-19 vaccines in more places, such as physicians’ offices or mobile clinics, that may not have the capacity or demand to keep multi-dose vials of COVID-19 vaccine on hand. It is the latest step in improving ease of access for COVID-19 vaccines and creates the potential for more equitable availability of this lifesaving product. The U.S. government will continue distributing multi-dose vials of the updated Pfizer vaccine for people 12 years of age or older through its distribution network that reaches more than 70,000 vaccine administration sites.

Renewal Deadline is January 2, 2023

The 2023 membership renewals have been prepared for all current members. We are pleased to inform you that 2023 membership renewal rates have remained the same with no increase. MSD has worked hard on your behalf and has expanded its reach to include environmental health and diversity, equity, and inclusion concerns, as well as our continued advocacy for physicians and patients in Delaware. Your 2023 membership renewal can be completed online by logging into the MSD website or by providing payment over the phone or through the mail. All 2023 individual membership renewals are due by January 2, 2023. Group renewals are due December 16, 2022. Please contact MSD Membership Manager Michelle Seymour with any questions at (302) 224-4905 or Michelle.Seymour@medsocdel.org.

MSD's Academic Channel Is Your Answer!

Are you looking to publish your original article, case or technical report? MSD has established a designated online "Academic Channel" for MSD within the Cureus Journal of Medical Science. As an author interested in publishing your work, this online, open access process will make it simpler and put you in control, keeping you informed every step along the way of the submission process. The streamlined online submission system and efficient editorial review process allows you to publish in weeks, not months. And since this is an open access model and published articles are indexed in PubMed Central, Web of Science, Google Scholar, and more, your work has global exposure. The peer review process leverages the collective intelligence of the Cureus community. We invite you to review the Medical Society of Delaware Academic Channel and consider submitting your work for publication. A separate Digital Digest is also published and distributed via email to members, delivering information about published articles, as well as other educational information. If you would like to join the team of peer reviewers on the Academic Channel, we'd love to have you! Please contact Mary LaJudice for more information.

Both Names to be Used Simultaneously for One Year

This week the Biden Harris Administration offered support for the World Health organization (WHO) announcement that it is renaming monkeypox disease to mpox. Mpox will become a preferred term, replacing monkeypox, after a transition period of one year to mitigate the concerns raised about confusion caused by a name change in the midst of a global outbreak. Federal public health agencies will adopt the mpox name in correspondence with the medical community and American public from this point forward. Mpox will be included in the ICD-10 online in the coming days and be part of the official 2023 release of ICD-11. Monkeypox will remain a searchable term in ICD to match historic information. This change from the WHO can help enhance the U.S. response to mpox by using a term that does not conjure bias or stigma and will aid efforts to reach the most impacted communities with a term for the disease that doesn't act to marginalize individuals from accessing the care, resources, and support they need to protect themselves and others.

HHS Proposes Protections to Increase Care Coordination and Confidentiality

On Monday, the U.S. Health and Human Services Department (HHS), through the Office for Civil Rights (OCR) and the Substance Abuse and Mental Health Services Administration (SAMHSA), announced proposed changes to the Confidentiality of Substance Use Disorder (SUD) Patient Records under 42 CFR part 2 (“Part 2”), which protects patient privacy and records concerning treatment related to substance use challenges from unauthorized disclosures. Specifically, the proposed rule increases coordination among physicians and other health care practitioners in the treatment for substance use challenges and increases protections for patients concerning records disclosure to avoid discrimination in treatment. This Notice of Proposed Rulemaking (NPRM) would implement provisions of Section 3221 of the Coronavirus Aid, Relief, and Economic Security Act (CARES Act) that, among other things, require HHS to bring Part 2 into greater alignment with certain aspects of the Health Insurance Portability and Accountability Act of 1996 (HIPAA) Privacy, Breach Notification, and Enforcement Rules. HHS encourages all stakeholders, including patients and their families, health insurance issuers, health care providers, health care professional associations, consumer advocates, and state and local government entities, to submit comments through regulations.gov.

Public comments on the NPRM are due 60 days after publication of the NPRM in the Federal Register. The NPRM may be viewed or downloaded at: https://www.federalregister.gov/public-inspection/2022-25784/confidentiality-of-substance-use-disorder-patient-records.

A fact sheet may be found at: https://www.hhs.gov/hipaa/for-professionals/regulatory-initiatives/hipaa-part-2/index.html.

School Record $18.36 Million Grant Awarded

Delaware State University (DSU) announced it has received a five-year, $18.36 million research grant from the National Institutes of Health (NIH) that will support the establishment of the Interdisciplinary Health Equity Research (IHER) Center on campus. This NIH funding is the largest research grant ever awarded to DSU in its 131-year history. The grant will enable the IHER Center to bring together a group of interdisciplinary faculty researchers, some focused on investigating the social and behavioral determinants of health and others using biomedical approaches to study the health conditions that have a disparate impact on underserved populations.

Multimedia Campaign Targeting Youth Ages 14-25

The Delaware Division of Public Health (DPH) announced the launch of a multimedia fentanyl campaign that targets youth, ages 14 through 25. This campaign aims to inform youth about what fentanyl is and that fentanyl can be found in various illicit drugs. This campaign highlights the risk of experimental drug use and the evolving drug market. National research on drug use in the U.S. demonstrates that many substance users do not think they are at-risk for a drug overdose. Many youths believe that fentanyl is an isolated issue or located within certain communities. This campaign empowers individuals to have control over their decisions by reducing the gaps in knowledge around fentanyl. Counterfeit prescription drugs laced with fentanyl have been sold through social media. This campaign utilizes these social media outlets to educate youth on the presence of fentanyl.  See Delaware statistics.

If someone is struggling with addiction in Delaware, call the DHSS 24/7 Crisis Hotline to be connected to treatment and recovery options. In New Castle County, call 1-800-652-2929. Or in Kent and Sussex counties, call 1-800-345-6785.

For free 24/7 counseling, coaching, and support, as well as links to mental health, addiction, and crisis services, call the Delaware Hope Line at 1-833-9-HOPEDE. To search for treatment and recovery services in Delaware or nearby states, visit HelpIsHereDE.com.

Hotline Makes Reporting Neglect, Abuse, Exploitation Easy and Confidential

The Delaware Division of Services for Aging and Adults with Physical Disabilities (DSAAPD) announced the launch of the new Adult Protective Services (APS) hotline. Concerned individuals and those experiencing harm can connect with free, voluntary services and resources that could save a life. Reporting through the hotline is confidential.

Under Delaware law, a vulnerable adult is defined as a person 18 years of age or older who, because of isolation, sickness, debilitation, mental illness, or physical, mental or cognitive disability, is easily susceptible to harm. 

Concerned individuals should call 888-APS-4302 if they suspect the occurrence of any forms of harm (physical abuse, sexual abuse, emotional abuse, neglect, self-neglect, exploitation, abandonment, mistreatment, intimidation, manipulation, or coercion). The hotline has operators answering the phone 24/7. APS is not a law-enforcement agency, though it does provide information obtained from a report of abuse to partner state agencies and law enforcement. APS may only intervene with its free services and resources if accepted by the victim. Victims themselves also can report harm and are urged to do so. 

While voluntarily reporting harm is highly encouraged, certain professions are legally mandated to report. Medical practitioners who have direct contact with a vulnerable adult and have reasonable cause to believe that the person may be subject to past, current or attempted abuse, neglect or exploitation have a duty to report the alleged harm. Caretakers and employees of financial institutions are also legally mandated to report. The hotline serves as a way for medical professionals to report suspected abuse. In addition, the DSAAPD is currently building a new online way to report, anticipated to be launched in the very near future and will be housed on their website at https://dhss.delaware.gov/dsaapd/aps.html.

For more information about Adult Protective Services, including how to file a report, types of harm, and the resources and services available, visit dhss.delaware.gov/dsaapd/aps. 

2023: Physician Medical Licensure Renewal Year

Delaware law requires that, in order for medical professionals to renew their license, they must attest that they have completed training on:

• how to recognize child sexual and physical abuse, exploitation and domestic violence
• your reporting obligations under the Medical Practice Act and Regulatory Provisions Concerning Public Health

The 2023 Mandatory Reporting Training for Medical Professionals will be available on January 1, 2023, and features videos from professionals within the child welfare field that walk participants through how to detect and respond to child abuse and neglect.

Licensed physicians must take the 2023 Mandatory Reporting training even if they recently completed mandatory reporting training. This training must be completed before every medical license renewal. Physicians are required to attest to completing the training on their renewal application. Failure to do so will delay the renewal of the medical license.  

This training is provided by the Office of the Child Advocate. To complete the training on or after January 1, 2023, go to https://stateofdelaware.csod.com/default.aspx?c=courts-oca to create an account. If you already have an account, just click the “login in” icon and sign in User ID and Password. Once training is completed, medical professionals can then reapply for licensure through the Division of Professional Regulation's website at https://delpros.delaware.gov/OH_HomePage.

Recruiting Hospital-Based Surgical Services Team to Join Free Program

Get the resources and training that your hospital-based surgical services need to practice robust surgical site infection (SSI) prevention – with a focus on MRSA. The Agency for Healthcare Research and Quality (AHRQ) is recruiting hospital-based surgical services teams to join this free 18-month program that begins in January 2023. Continuing education credits will be offered at no charge for participants. As a subset of antibiotic-resistant infections, MRSA incidence stabilized from 2017 to 2020 after years of decreases, but continues to be a serious threat, with more than 323,000 cases detected in hospitalized patients and over 10,000 deaths annually. In addition, MRSA infections increased 13 percent during the first year of the COVID-19 pandemic.

The AHRQ Safety Program for MRSA Prevention provides participating surgical services teams with technical assistance, coaching, webinars, and tools to support your infection prevention program.

Please join for an informational webinar to learn more about the program.

• Friday, December 2, 11 a.m. ET REGISTER
• Wednesday, December 7, 11 a.m. ET REGISTER
• Tuesday, December 13, 4 p.m. ET REGISTER
• Tuesday, December 20, 12 p.m. ET REGISTER
• Wednesday, January 4, 10 a.m. ET REGISTER
• Monday, January 9, 2 p.m. ET REGISTER

For more details on this program and to find out if you qualify to participate, visit https://safetyprogram4mrsaprevention.org/

This program is funded and guided by the Agency for Healthcare Research and Quality and led by Johns Hopkins Armstrong Institute for Patient Safety and Quality and NORC at the University of Chicago.

HHS Office for Civil Rights, Department of Justice Webinar - Thursday, Dec 8

Under federal law, patients have the right to access health care, free of discrimination. Please join the United States Department of Justice and the HHS Office for Civil Rights Director Melanie Fontes Rainer for a briefing on President Biden's Executive Order on Securing Access to Reproductive and Other Healthcare Services. This 30-minute briefing will outline existing OCR guidance and focus on issues of concern for hospitals, clinics, and physicians on compliance with federal law. Please register for this important conversation.

Date: Thursday, December 8th, 2022

Time: 3:00 PM – 3:30 PM ET

Please register using this link

Please submit questions for the Q&A segment of the webinar through the registration form. 

HRSA Seeking Nominations for Qualified Candidates to Be Considered

The Health Resources and Services Administration (HRSA) is seeking nominations for qualified candidates to be considered for appointment to the Advisory Committee on Infant and Maternal Mortality (ACIMM). ACIMM advises the Secretary of the U.S. Department of Health & Human Services (HHS) on department activities, partnerships, policies, and programs directed at reducing infant mortality, maternal mortality, and severe maternal morbidity. The committee advises the HHS Secretary on how to improve the health status of infants and women before, during, and after pregnancy. Nominees sought are medical, technical, or scientific professionals with special expertise in the field of maternal and child health, in particular infant and/or maternal mortality and related health disparities; members of the public having special expertise about or concern with infant and/or maternal mortality; and/or representatives from such public health constituencies, consumers, and medical professional societies. Interested applicants may self-nominate or be nominated by another individual or organization. ACIMM consists of members appointed by the Secretary and individuals selected for appointment to the Committee will be invited to serve for up to 4 years. Read the Federal Register Notice and submit nominations by Monday, January 23, 2023.

FDA Issues Two Guidance Documents to List Major Food Allergen on Labels

The U.S. Food and Drug Administration (FDA) issued two guidance documents about food allergen labeling requirements to help the food industry meet the requirements to list any major food allergen on the labels of FDA-regulated foods. One of the guidance documents is a draft guidance titled Questions and Answers Regarding Food Allergens, Including the Food Allergen Labeling Requirements of the Federal Food, Drug, and Cosmetic Act (Edition 5); Guidance for Industry. This draft guidance updates the previous edition (Edition 4) with new and revised questions and answers related to the labeling of food allergens, including requirements in the Food Allergy Safety, Treatment, Education, and Research Act of 2021 (FASTER Act) and the Food Allergen Labeling and Consumer Protection Act of 2004 (FALCPA). The FALCPA amended the Federal Food, Drug, and Cosmetic Act (FD&C Act) by defining the term “major food allergen” and requiring that foods or ingredients that contain a major food allergen be specifically labeled with the name of the allergen source. This law identified eight foods as major food allergens: milk, eggs, fish, shellfish, tree nuts, peanuts, wheat, and soybeans. The FASTER Act, among other things, adds sesame to the list of major food allergens effective January 1, 2023, which will make it the ninth major food allergen recognized in the U.S.

CDC Soliciting Comment on Proposed Hep C Virus Testing Recommendations

The Centers for Disease Control and Prevention (CDC) in the Department of Health and Human Services (HHS) announces publication of proposed recommendations for perinatal HCV testing in the Federal Register. The deadline to provide public comment is January 27, 2023. 

To view the proposed recommendations, please visit regulations.gov (docket # CDC-2022-0016) or the Federal Register (found under the Notices section of the 2022 Index). 

On Tuesday, December 6, 2022 at 3:00 pm EST a webinar will be presented to learn more about the proposed recommendations. Registration is required.

Podcast with Paul Offit, MD

Get details on everything parents and physicians need to know about respiratory syncytial virus (RSV) from Paul Offit, M.D., director of the Vaccine Education Center and attending physician in the Division of Infectious Diseases at Children's Hospital of Philadelphia. Dr. Offit is also a member of the US Food and Drug Administration's (FDA's) vaccine advisory committee. Listen now on Apple Podcasts or Simplecast. American Medical Association Chief Experience Officer (CXO), Todd Unger, hosts.

Empower Patients to Take Charge of Their Own Health

Did you ever want to prevent, arrest, and reverse chronic disease, decrease medication, and feel better? Or perhaps a certain pool of your patients would benefit from a lifestyle change?

The Rochester Life Medicine Institute presents the "Jumpstart 15 Day Whole-Foods Plant-Based Program" that teaches participants how to eat the right foods to heal and reverse chronic conditions, such as heart disease, type 2 diabetes, high blood pressure, and obesity. Many participants report that they were able to greatly reduce or even eliminate their medications after taking the program. The program follows a whole-food plant-based approach to eating, scientifically proven to give you your health back. The Rochester Life Medicine Institute's 15-Day Jumpstart Program is one of 4 programs certified by the American College of Lifestyle Medicine. The Rochester Life Medicine Institute is a nonprofit organization, well-respected for offering high value evidence-based services. They offer an educational program for physicians and other health professionals, with 10+ free hours of CME (choose the Jumpstart Health "Comprehensive" or "Live Participation" course and use discount code freeCME at checkout; choose a month to register for the 15-day Jumpstart Program - do not enter credit card info - and apply discount code JSCMEclinician at checkout). This program can help physicians earn CME credit and learn new skills that can also be used with their patients. Learn more about the Jumpstart Program.

MSD's My Green Doctor Explains How Your Patients Can Avoid Them

Per- and PolyFluoroAlkyl Substances (known as PFAS chemicals) seem to be everywhere these days: at the top of Mount Everest, in umbilical cord blood, in breast milk, and in the news.  In 2022, the U.S. Environmental Protection Agency announced new health advisories for PFAS in drinking water. MSD’s My Green Doctor explains PFAS and how your patients can avoid them. https://mygreendoctor.org/pfas-toxic-chemicals-to-understand-avoid/

My Green Doctor is a free money-saving membership benefit from the Medical Society of Delaware. Members use My Green Doctor’s “Meeting-by-Meeting Guide” to learn how to adopt environmental sustainability, save resources, and help create healthier communities. The program adds just five minutes to each regular office staff meeting or weekly office “huddle”, making small changes at each meeting that really add up over time. Everyone in your practice can register as Partner Society members at www.MyGreenDoctor.org or at www.MyGreenDoctor.es (si, en Espanol). Use the discount code MGDMSD to save $60 instantly and get full free access to My Green Doctor forever. Ask your practice manager to register today and to put My Green Doctor on your next agenda. You can do this!

ChristianaCare

ChristianaCare has named its Breast Center The Tatiana Copeland Breast Center at the Helen F. Graham Cancer Center & Research Institute in recognition of Gerret and Tatiana Copeland’s generous financial support. The Copelands, local philanthropists and business entrepreneurs, provided a $1.2 million gift to the Graham Cancer Center in 2019 for breast cancer prevention and research for underrepresented women. Tatiana Copeland previously provided $800,000 to fund the purchase of two 3D mammography units. As a result of their philanthropic leadership, the Graham Cancer Center was one of the first facilities in the nation to offer 3D mammography.

Louisa C. Mankin, MD, Age 103

It is with sadness that we inform of the passing of MSD member Louisa Claflin Mankin on November 24th at the age of 103. Dr. Mankin joined MSD as a member in 1950. She studied medicine at Temple University and was one of only nine women in the graduating class of 1947. She worked in the Wilmington Public Schools from 1948 to I951, where she served as the district's first full-time physician, then at the Governor Bacon Health Center from 1951-1952, and later resumed working on a part-time basis for the Wilmington and Newark School districts. In 1971, Dr. Mankin was appointed by Delaware Governor Russell Peterson to serve a three-year term on his newly created Governor's Council for Women. The Council's purposes at that time included determining the nature and extent of discrimination against women in Delaware and fostering understanding of and appreciation for the contributions women could make to the growth and progress of the state and nation. In 1973 she was hired as a full-time physician for the University of Delaware Health Service where she continued until her retirement in 1986. After retiring she spent time as a volunteer lecturer for the American Cancer Society and served as transportation coordinator for the Road to Recovery Program. Service and burial will be private. Read obituary.

Sarah E. Nicholls, PA - ChristianaCare Oncology Hematology

John Viteritti, DO - Highmark, Inc.

MSD members are afforded a seven-day review period from the date of this publication to comment regarding applicants for membership. Please contact Michelle Seymour at (302) 224-4905 or Michelle.Seymour@medsocdel.org with any comments on the current pending member(s) listed above.

• DPH Flu Dashboard
• DPH Delaware Weekly Influenza Surveillance Reports by week.
• CDC https://www.cdc.gov/flu/weekly/index.htm
• WHO https://www.who.int/teams/global-influenza-programme/surveillance-and-monitoring/influenzaupdates/current-influenza-update

• DPH Public Health Alerts: de.gov/publichealthalerts
• DPH Hotline - (866) 408-1899 (Monday -Friday, 8:30 a.m. to 4:30 p.m.) or DPHCall@delaware.gov
• Reporting suspected monkeypox rash in Delaware: Contact DPH Office of Infectious Disease Epidemiology (OIDE), at 302-744-4990 (business hours) or 1-888-295-5156 (after hours).
• Delaware health care facilities that require specimen collection kits can order through OEMS@delaware.gov using a SHOC Request form.
• DPH website: de.gov/monkeypox
• DPH Social Channels: Facebook (@DEPublicHealth), Instagram (@depublichealth), DHSS Twitter (@Delaware_DHSS)
• FDA Monkeypox Response Website
• CDC Monkeypox Website
• CDC Case Definitions for 2022 Monkeypox Response
• CDC Considerations for Monkeypox Vaccination for the recommended use of vaccine in the U.S.
• CDC Monkeypox Treatment Information for Healthcare Professionals
• Specimen collection: Follow Lab Advisory: CDC Updates Specimen Collection Guidelines for Monkeypox Virus 

• COVID-19 by County Community Level Check (# hospital admissions and beds used and total number of new cases)
• COVID-19 Community Transmission (based on cases per 100,000 people and positivity rate, both measured over the last 7 days)
• Fact Sheet: Data Points on Bivalent COVID-19 Vaccination (November 16, 2022)
• DPH Public Health Alerts: de.gov/publichealthalerts
• DPH COVID-19 Booster Information: de.gov/boosters
• Federal website for information on navigating COVID: COVID.gov
• CDC COVID-19 Quarantine and Isolation Calculator
• COVID-19 Treatment Options
• Medical Provider Guidance for Administering Therapeutics
• COVID-19 Therapeutics Locator
• CDC COVID Data Tracker Weekly Review.
• For testing flyers (available in English, Spanish, Haitian Creole): https://covidmaterialsde.com/resources/community-organizer
• For all testing site referral locations, visit: de.gov/gettested
• For vaccination site referral locations, visit: de.gov/getmyvaccine
• Pfizer-BioNTech COVID-19 Vaccine Presentation Wall Chart (updated November 15, 2022)
• Pfizer/Moderna pediatric vaccine information: de.gov/youthvaccine
• FDA At-Home OTC COVID-19 Diagnostic Tests provides a list of all FDA-authorized at-home over-the-counter (OTC) COVID-19 diagnostic tests
• Know the COVID-19 Community Level where you live
• DPH COVID-19 Vaccine Fact Check Page to help separate fact from fiction.
• Subscribe to the COVID-19 Update podcast - on Apple Podcasts or Simplecast.